JYJianda Yuan

Jianda Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianda Yuan has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma

    by Nicolas Jacquelot, David P. Enot, Caroline Flament, Nadège Vimond, Carolin Blattner, Jonathan M. Pitt, Takahiro Yamazaki, María Paula Roberti, Romain Daillère, Marie Vétizou, et al.

    Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functional behavior of which is guided by chemokine or cytokine gradients. Here, we retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma (MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression correlates with intratumoral accumulation, metastatic progression, and/or overall survival (OS). Homing receptor expression on lymphocytes strongly correlated with MMel dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+ naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. The expansion of CLA-expressing effector memory CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic approaches.


  • Open Access

    Immune Monitoring Technology Primer: protein microarray (‘seromics’)

    by Jianda Yuan, Ena Wang, Bernard A. Fox

    Protein microarrays are used to identify targets of drugs, small molecules, and enzyme substrates that may be modified in numerous ways such as by phosphorylation or methylation, to detect protein binding properties, investigate protein-protein interactions, and to define protein-based biomarkers in a high-throughput manner. They are based on the development of DNA microarray techniques and have thousands of purified proteins immobilized on a solid surface. The technique requires a blocking step to be applied to remove any non-specific binding. After incubation of the protein probe (e.g. patient serum) with a suitable tag, visible detection reagents are employed to quantify the corresponding signals. Proteins microarray are classified into three types: analytical, functional and reverse-phase protein microarrays [1]. Functional protein microarrays are widely used because of their commercial availability. As an example, ProtoArray® offers a unique approach to analyze the serological response against thousands of proteins (~9000) simultaneously. ProtoArray® does not cover the entire proteome, but a serological analysis of clinical samples using this protein microarray allows high-content "seromics” screening against a substantial portion of the human proteome to identify potential antibody biomarkers and reactivity patterns that may correlate with disease state or treatment response.


  • Open Access

    Quantitative real-time PCR assisted cell counting (qPACC) for epigenetic - based immune cell quantification in blood and tissue

    by Thomas Oliver Kleen, Jianda Yuan

    A novel form of immune cell quantification in blood and tissue is described using epigenetic - based, quantitative real-time PCR assisted cell counting (qPACC). The methylation status of the chromatin structure of either actively expressed or silenced genes is the basis of the epigenetic-based cell identification and quantification technology. Discovery of cell type specific removal of methyl groups (demethylation) from the 5′-carbon of the cytosine base in the dinucleotide cytosine phosphate guanine permits precise and robust quantification of immune cells from only small amounts of human blood or tissue samples. These epigenetic biomarkers located on genomic DNA are stably associated with a cell type of interest.


  • Open Access

    Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

    by Michael A. Postow, Manuarii Manuel, Phillip Wong, Jianda Yuan, Zhiwan Dong, Cailian Liu, Solène Perez, Isabelle Tanneau, Marlène Noel, Anaïs Courtier, et al.

    Background Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with cancer, but its relevance as a biomarker for ipilimumab outcomes remains unknown. Findings In this pilot study, we analyzed the pre-treatment peripheral blood TCR repertoire in 12 patients with metastatic melanoma who received ipilimumab at 3 mg/kg (clinical benefit, n = 4; no clinical benefit, n = 8). TCR diversity was evaluated using a polymerase chain reaction assay which measures TCR combinatorial diversity between V and J genes from genomic DNA. TCR repertoire diversity was studied through richness (observed V-J rearrangements) and evenness (similarity between the frequencies of specific V-J rearrangements). The Wilcoxon rank sum test was used to compare patients with clinical benefit and those without. Association with benefit in a dichotomized analysis was assessed through a Fisher’s exact test. Overall survival was studied through log-rank analysis. There was a significant difference in richness (p = 0.033) and evenness (p = 0.028) between patients with and without clinical benefit. Dichotomized analysis showed that none of the patients with low richness (n = 0/5, p = 0.081) nor low evenness (n = 0/7, p = 0.01) achieved clinical benefit. There were no significant differences in overall survival. Conclusions In this small group of patients, baseline TCR diversity in the peripheral blood was associated with clinical outcomes. Further investigation is ongoing in larger cohorts of patients to explore these preliminary findings and determine whether TCR diversity can be used as a predictive biomarker in cancer immunotherapy.


  • Presence of myeloid-derived suppressor cells (MDSC) in patients with metastatic castration-sensitive and castration-resistant prostate cancer.

    by Karen A. Autio, Phillip Wong, Angel Rabinowitz, Jianda Yuan, Lauryn Michelle Slavin, Ryan Brennan, Melineh DerSarkissian, Zhenyu Mu, Howard I. Scher, Alexander M. Lesokhin

    222 Background: MDSC contribute to an immune suppressive environment and have been implicated in cancer progression. Measurement (identification and enumeration) is challenged by the lack of analytically valid assays limiting data interpretation between groups. This impacts our understanding of rationale immune targets and design of clinical trials. We employed a novel biomarker based assay in whole blood to enumerate MDSC from patients with metastatic castration sensitive (CSPC) and castration resistant prostate cancer (CRPC). Methods: Whole blood was collected in Cyto-Chex (Streck) tubes. A published computational algorithm-based approach (developed by Memorial Sloan Kettering Cancer Center and commercialized by Serametrix) was employed to determine the %MDSC-monocytic and coefficient of variance (CV=ratio of SD and geometric mean fluorescence intensity) to assess HLA-DR spread on CD14+CD11b cells. Samples were performed in duplicate. Clinical variables including clinical state, past and current treatment, metastatic sites, PSA, and standard prognostic markers were collected. Results: 36 pts with metastatic prostate cancer (29 CRPC; 7 CSPC) were included. Median (SD) %MDSC in 29 CRPC pts was 21.15 (5.33) and median (SD) CV was1.29 (0.25); 7 CSPC demonstrated a median (SD) %MDSC 19.15 (4.86) and median (SD) CV 1.22 (0.25). MDSC did not differ between chemotherapy exposed (n=13) and chemotherapy naive (n=16) CRPC (23.3 vs 19.5, p=ns). MDSC were not significantly higher in those with visceral mets, though a trend existed (20.3 vs 24.0, p=0.076). PSA did not appear to correlate with MDSC or CV. Conclusions: Understanding the distribution and characterization of MDSC in various clinical states in prostate cancer is relevant to the development of immune targets in this disease. MDSC were quantifiable in both CSPC and CRPC. There was a trend for higher MDSC values in patients with visceral metastases, which historically are associated with worse prognoses. Presence of MDSC in metastatic CSPC and CRPC has important therapeutic and trial implications. Further discovery in larger cohorts and earlier disease states is underway.


  • The neoantigen landscape underlying clinical response to ipilimumab.

    by Alexandra Snyder Charen, Vladimir Makarov, Taha Merghoub, Logan Walsh, Jianda Yuan, Martin Miller, Kasthuri Kannan, Michael Andrew Postow, Ceyhan Elipenahli, Cailian Liu, et al.

    3003 Background: Ipilimumab, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), prolongs overall survival and can produce durable tumor regression in patients with advanced melanoma. Ipilimumab activates cytotoxic T-lymphocytes and enables them to destroy tumor cells. However, the molecular determinants of response to ipilimumab are unknown. Methods: Fresh frozen tumor DNA (and matching blood) from 25 melanoma patients treated with ipilimumab was subjected to whole exome sequencing. Exon capture was performed using the SureSelect Human All Exon 50MB kit (Agilent). Enriched exome libraries were sequenced on the HiSeq 2000 platform (Illumina) to a mean coverage of 103X. Somatic mutations and candidate somatic neoantigens generated from these mutations were identified and characterized. Results: Our cohort included complete responders (CR) and nonresponders (NR). Mutational burden ranged from 1-1121 mutations per tumor. Mutational load was significantly associated with clinical response (p=0.028, CR vs. NR, Fisher’s Exact Test), but alone was not sufficient to predict response. Using genome-wide somatic neoepitope analysis, we defined candidate tumor neoantigens and identified a neoantigen landscape that is specifically present in tumors with complete responses to ipilimumab. These somatic neoepitopes share consensus sequences with experimentally validated antigens from a variety of pathogens. Furthermore, in four of six CR patients, a mutation led to the generation of a consensus amino acid sequence previously identified as necessary for T-cell recognition of melanoma antigen recognized by T-cells (MART-1). Conclusions: Somatic mutations and concomitant generation of neoepitopes in melanoma tumors confers enhanced antigenicity and response to the immune checkpoint modulator ipilimumab. Our study defines the neoantigen landscape in responders to ipilimumab, provides a rationale for examining the exomes of patients for whom ipilimumab is being considered, and builds a foundation for understanding the molecular determinants of response to cancer immunotherapy.


  • A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).

    by Adi Diab, Heather L. McArthur, Stephen Barnett Solomon, Virgilio Sacchini, Christopher Comstock, Majid Maybody, Jeremy C. Durack, Brian Blum, Jianda Yuan, Sujata Patil, et al.

    1098 Background: Because intratumoral cryo with immune modulation generates a potent systemic anti-tumor immune response in murine models, this strategy may improve outcomes for women with ESBC. In this study, we evaluated the safety of pre-op cryo and/or ipi (10mg/kg) in ESBC pts and explored immune correlates including tumor infiltrating lymphocytes (TILs). Methods: Eligibility: age ≥18y with operable ≥1.5 cm invasive ESBC planning mastectomy (TM). Pts were sequentially assigned to receive pre-op: cryo alone (group A), ipi alone (B), or ipi and cryo (C). Tissue biopsies and/or cryo were performed 7-10d prior to TM. Ipi was administered 8-15d prior to TM (1-5d prior to cryo). The regimen was to be considered safe/tolerable if at least 5/6 pts in each group proceed to TM without delay. Toxicity evaluation continued for 30d after TM for group A and 12wks after ipi administration for groups B&C. Research peripheral bloods for immune correlates were obtained at baseline, biopsy, TM and 2-3 wks thereafter. Blood, biopsy and TM samples were evaluated by flow-cytometry. Results: The study is complete. Pre-op cryo-alone, ipi-alone and the combination were well tolerated and the primary safety endpoint was achieved with all 19 enrolled pts undergoing TM without delay. Group A was expanded to 7 pts after a possible technical failure in 1 pt, 6 pts enrolled to group B and 6 pts enrolled to group C. Median age was 48y (range 34-72y). Tumor necrosis/infarction was observed in 9/12 pts who underwent cryo. A trend toward an increased frequency of blood CD4+ICOS+, CD8+ICOS+, CD4+Ki67+ and CD8+Ki67+ T-cells was observed at TM compared with baseline in the ipi treated groups only. Analysis of TILs in the TM specimens suggested a higher ratio of CD8+Ki67+ T-cells to CD4+CD25+FOXP3+ (T-regulatory) cells in group C when compared with A&B. Conclusions: Pre-op cryo and ipi, alone or in combination, are safe/tolerable in pts with ESBC. Immune correlates revealed activation of T-cells in the blood in single-dose ipi treated pts and a modest increase in the ratio of tumor CD8+Ki67+ T-cells to T-regulatory cells after combination therapy only. A Phase II study of pre-op ipi and cryo in ESBC is planned. Clinical trial information: NCT01502592.


  • A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).

    by Adi Diab, Stephen Barnett Solomon, Christopher Comstock, Majid Maybody, Virgilio Sacchini, Jeremy C. Durack, Brian Blum, Jianda Yuan, Sujata Patil, Deirdre A. Neville, et al.

    67 Background: Intratumoral cryo combined with immune modulation generates a potent systemic anti-tumor immune response that might improve recurrence free survival in ESBC. In this study, we evaluate the safety of pre-op cryo and/or ipi (10mg/kg) in pts with ESBC. Radiographic correlates and intratumoral/serologic immune responses are also explored. Methods: Eligible pts are ≥18y of age with operable ≥1.5 cm invasive ESBC, no history of autoimmune disease and planned mastectomy. Pts are sequentially assigned to receive pre-op: cryo alone (Group-A), ipi alone (B), or ipi with cryo (C). Cryo is administered 7-10d prior to surgery. Ipi is administered 8-15d prior to surgery (1-5d prior to cryo). If at least 5/6 pts in each group proceed with surgery without delay, the regimen will be considered safe/tolerable. Toxicity evaluation continues for 12 wks after ipi administration for Groups B and C. Results: As of May 1, 2013, 7/7 pts were enrolled to Group-A (expanded after a possible technical failure in 1 pt) and 6/6 pts were enrolled to Group-B. The median age was 45y (range 39-69y). All 13 pts in Groups A and B underwent mastectomy without delay. Group C is now accruing with 1/6 patients enrolled and awaiting surgery. 6/7 pts in Group-A and none in Group-B had ischemic tumor necrosis/infarction in the mastectomy tissue. Overall, pre-op cryo or ipi alone have been well tolerated with no study related grade 3/4 adverse events (AE) reported (Table). Conclusions: To date, pre-op cryo or ipi is safe and tolerable in pts with ESBC. A Phase II study of pre-op ipi and cryo in ESBC is planned. Clinical trial information: NCT01502592. [Table: see text]


  • Open Access

    Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

    by Jianda Yuan, Geoffrey Y Ku, Matthew Adamow, Zhenyu Mu, Sapna Tandon, Drew Hannaman, Paul Chapman, Gary Schwartz, Richard Carvajal, Katherine S Panageas, et al.

    Prior studies show that intramuscular injection and particle-mediated epidermal delivery of xenogeneic melanosomal antigens (tyrosinase or Tyr, gp100) induce CD8+ T cell responses to the syngeneic protein. To further define the optimal vaccination strategy, we conducted a phase I study of in vivo electroporation (EP) of a murine Tyr DNA vaccine (pINGmuTyr) in malignant melanoma patients.